

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AL001
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : AL001
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AL001
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : AL001
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 22, 2021

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 05, 2020

Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 17, 2019

Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 17, 2018
